Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

In this section

2016 FAQ's

The monthly frequently asked questions are compiled by DIG faculty, residents, and students.  These summaries provide a concise overview of a current drug therapy topic.

2016 FAQs


What is the optimal dosing of 4-factor prothrombin complex concentrate in patients with warfarin-associated bleeding?

Is there updated information on the off-label use of dexmedetomidine (Precedex®) for alcohol withdrawal syndrome?

What is the available evidence for the use of sodium thiosulfate for non-uremic calciphylaxis?


What drugs can be used to manage floppy iris syndrome during cataract surgery?

What is the latest information on gadolinium-based contrast agents and brain deposits?

Is there literature to support the adjunct use of simethicone prior to colonoscopy to improve visualization?


What are the data on efficacy and safety of using injectable tobramycin for inhalation via nebulization?

What are the comparative clinical data for albuterol versus levalbuterol?

What evidence supports the efficacy of ranolazine (Ranexa®) for the treatment of atrial fibrillation?


Dexrazoxane and the risk secondary cancer in pediatric patients: Can this controversy be laid to rest?

What are alternatives to sublingually administered ophthalmic atropine for treatment of noisy breathing in terminally ill patients?

How should medications be appropriately managed following bariatric surgery?


What evidence supports the use of antibiotic-loaded bone cement to prevent infection in primary hip and knee arthroplasty?

What does the American Psychiatric Association recommend regarding the use of antipsychotics in patients with dementia?

Can a simplified 2-bag acetylcysteine approach improve tolerability in acetaminophen overdoses?


What evidence is available for the use of fluorescein for gastrointestinal and genitourinary procedures?

What is the evidence to support the new 2016 heart failure update and place in therapy of the new heart failure agents?

What is the comparative evidence on use of IV acetaminophen versus oral acetaminophen? 


What evidence is available for efficacy and stability of high dose mitomycin C concentrations?

What evidence supports or refutes the use of medical grade honey for wound healing?

What are the new 2016 ACC/AHA guideline recommendations for dual antiplatelet therapy?


What are the key changes to drug therapy recommendations in the 2016 AACE type 2 diabetes algorithm? 

What are the clinical implications of the 2016 American Epilepsy Society (AES) guidelines for status epilepticus?

What is the clinical evidence for the use of sugammadex (Bridion®)?


What are the 2016 guideline recommendations for the management of postoperative pain?

What is the most recent evidence for using probiotics in patients with Clostridium difficile

Does adjunctive corticosteroid therapy improve outcomes in patients with community-acquired pneumonia?


What data support selexipag and initial ambrisentan/tadalafil therapy for pulmonary arterial hypertension?

What information is available on Zika virus infection?

What are the major drug-related changes to the 2016 update of the CHEST Guideline for Antithrombotic Therapy for VTE Disease?


Do the insulin glargine products Basaglar and Lantus have similar safety and efficacy profiles?

Should blood pressure goals be lowered based on recent evidence?

Are proton pump inhibitors (PPIs) associated with negative outcomes in patients with cirrhosis?


What data are available comparing liposomal bupivacaine to other agents?

Can estimated patient weight be safely used for dosing of alteplase for acute ischemic stroke?

What are the key features of the new rheumatoid arthritis guidelines?